C4 Therapeutics, Inc. · NASDAQ:CCCC
C4 Therapeutics — Corporate Update (August 2025)
23 slides from C4 Therapeutics's corporate update, Aug 7, 2025
Slide 1: Protein degraded. Disease targeted. Lives transformed.
Protein degraded. Disease targeted. Lives transformed. August 2025
Slide 2: Forward-looking Statements and Intellectual Property
Forward-looking Statements and Intellectual Property FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,”
Slide 3: Our Mission
Our Mission To deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients’ lives. Our portfolio of degrader medicines pursues targets that may benefit from a degrader approach: Cemsidomide1 targeting IKZF1/3 for multiple myeloma and
Slide 4: C4T Has Been at the Forefront of TPD Science
C4T Has Been at the Forefront of TPD Science and Is On the Path to Becoming a Fully Integrated Biotechnology Company © 2025 C4 Therapeutics, Inc. Built TORPEDO platform to design highly catalytic, orally bioavailable degraders Established collaborations with leading global pharmaceutical companies,
Slide 5: MM Focused Pipeline to Advance a Portfolio of Degrader Medicines
PROGRAM TARGET INDICATIONS RESEARCH PRECLINICAL EARLY DEVELOPMENT LATE DEVELOPMENT RIGHTS Cemsidomide1 IKZF1/3 Multiple Myeloma & Non-Hodgkin’s Lymphoma CFT89192 EGFR L858R Non-Small Cell Lung Cancer CFT19463 BRAF V600 Mutant V600 Mutant Cancers Discovery Programs Oncology & Non-oncology Indications
Slide 6: Prioritized Portfolio with Multiple 2025 Milestones
Prioritized Portfolio with Multiple 2025 Milestones © 2025 C4 Therapeutics, Inc. Cemsidomide IKZF1/3 2Q 2025: Completed Phase 1 dose escalation in MM September 2025: Present data from full Phase 1 dose escalation in MM at IMS Annual Meeting 4Q 2025: Present data from Phase 1 dose escalation data in
Slide 7: Advancing Oncology and Non-oncology Discovery Programs With Collaboration Partners
Advancing Oncology and Non-oncology Discovery Programs With Collaboration Partners © 2025 C4 Therapeutics, Inc. Evaluating targets in autoimmune diseases & oncology Advanced two programs to preclinical milestones Discovering targeted protein degraders against critical oncogenic proteins Focused on t
Slide 8: Cemsidomide IKZF1/3 Degrader
Cemsidomide IKZF1/3 Degrader Multiple Myeloma & Non-Hodgkin’s Lymphoma
Slide 9: IKZF1/3 Are Key Promoters of Myeloma and Lymphoma Cell Survival
IKZF1/3 Are Key Promoters of Myeloma and Lymphoma Cell Survival and Will Remain Important Therapeutic Targets for These Indications Multiple myeloma (MM); non-Hodgkin’s lymphoma (NHL) Hematopoietic Stem Cell Common Myeloid Progenitor Cell Common Lymphoid Progenitor Cell Neutrophil Platelets T-Cell B
Slide 10: Cemsidomide Enrollment and Dose Escalation Complete in MM
Cemsidomide Enrollment and Dose Escalation Complete in MM 100 µg QD 75 µg QD 62.5 µg QD 37.5 µg QD 50 µg MWF DOSE ESCALATION CEMSIDOMIDE 14/14 + DEX* Utilizing a Bayesian logistic regression model until determination of the MTD and/or RP2D © 2025 C4 Therapeutics, Inc. KEY INCLUSION CRITERIA • Adults
Slide 11: Cemsidomide MM Data Further Demonstrate Potential Best-in-Class Profile
11© 2025 C4 Therapeutics, Inc. Cemsidomide MM Data Further Demonstrate Potential Best-in-Class Profile Cemsidomide continued to be well-tolerated with manageable neutropenia1 0% 25% 50% 75% 100% All Dose Cohorts (N=63) 75 µg Cohort (N=20) 100 µg Cohort (N=10) R e sp o n se R a te ORR 33% ORR 40% ORR
Slide 12: Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy
TEMRA TEM 0 20 40 60 80 100 % positive cells (C1D21 vs C1D1) % p o s it iv e c e ll s C1D1 C1D21 © 2025 C4 Therapeutics, Inc. Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy ** **** TEMRA: Terminally differentiated T-cells TEM: Effector memory T-cells Peripheral blood mono
Slide 13: Immune T-Cell Activation Has Potential to Enhance Bispecific T-cell Engager Therapies
Immune T-Cell Activation Has Potential to Enhance Activity of Bispecific T-cell Engager Therapies Validated Biology Precedent Clinical Evidence 2 Preclinical Cemsidomide Data Cemsidomide enhances the activity of bispecific T-cell engagers through immunomodulation Talquetamab +/- IKZF1/3 Degraders In
Slide 14: Cemsidomide Development Plan Addresses Multiple Lines of Therapy
Phase 2 (Single Arm) Cemsidomide + Dex For registrational intent Cemsidomide Development Plan Addresses Multiple Lines of Therapy I 2L ~56,000 1L ~65,000 3L ~49,000 4L ~42,000 5L+ ≥23,000 U.S. + EU4 + UK Addressable Patients (2024)1 Treatment Line Phase 1b Cemsidomide / BCMA Bispecific Combo Studies
Slide 15: Cemsidomide Positioned to Be an IKZF1/3 Degrader of Choice
With a Potential Best-in-Class Profile, Cemsidomide Is Positioned to Be an IKZF1/3 Degrader of Choice Across Various Combinations Post-Transplant Maintenance1 Anti-CD38 Combos Proteasome Inhibitor Combos CAR-Ts (+/- Maintenance Therapy) Other MOAs2 1Approximately 30% of multiple myeloma patients und
Slide 16: Cemsidomide Enrollment and Dose Escalation Is Complete in NHL
Cemsidomide Enrollment and Dose Escalation Is Complete in NHL © 2025 C4 Therapeutics, Inc. KEY INCLUSION CRITERIA • Adults with NHL, R/R to prior therapy • PTCL patients must have received at least 1 prior alkylator-based chemotherapy • ALCL patients must have also received a CD-30 mAb • Nonresponsi
Slide 17: CFT8919 EGFR L858R Degrader
CFT8919 EGFR L858R Degrader Non-Small Cell Lung Cancer
Slide 18: CFT8919 Is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R
CFT8919 Is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R With Potential to Improve Outcomes for NSCLC Patients CFT8919 Orthosteric Inhibitor Potential Degrader Advantages of CFT8919: CFT8919 exploits an allosteric binding site created by the L858R mutation, thereby avoiding res
Slide 19: CFT8919 Binds to Allosteric Site, Avoiding Impact of Co-mutations
CFT8919 Binds to Allosteric Site, Avoiding Impact of L858R Non-classical Co-mutations in the Orthosteric Binding Pocket Sources: 1. From Black Diamond’s analyses of 94,939 sequencing reports from treatment naive NSCLC (Guardant Health) presented at AACR 2024 (https://blackdiamondtherapeutics.com/ass
Slide 20: CFT8919 Is Selective for EGFR L858R and Active in Osimertinib Resistance
Mean plasma concentration shown for n > 2 Mean plasma concentration shown for n > 2 CFT8919 Is Selective for EGFR L858R and Active in a Setting of Osimertinib Resistance in Preclinical Models Source: C4T data on file; Presented at Keystone Symposium 2021 (https://c4therapeutics.com/wp-content/upload
Slide 21: CFT8919 Demonstrates Activity in Brain Metastasis Model
Mean plasma concentration shown for n > 2 Mean plasma concentration shown for n > 2 Mean plasma concentration shown for n > 2 CFT8919 Demonstrates Activity in Brain Metastasis Model Source: C4T data on file; presented at TPD Summit 2021 (https://c4therapeutics.com/wp-content/uploads/C4_CFT8919_TPD_S
Slide 22: CFT8919 Has the Potential to Address Multiple Opportunities With High Unmet Needs
CFT8919 Has the Potential to Address Multiple Opportunities With High Unmet Needs CFT8919’s Fastest Path to Market Is in 2L+ With Potential to Expand Into Front-Line Development Rationale: • Fast path to market • Lack of therapies after patients relapse with secondary mutation (i.e., C797S) 2L+ Deve
Slide 23: Prioritized Portfolio With Multiple 2025 Milestones
Prioritized Portfolio With Multiple 2025 Milestones © 2025 C4 Therapeutics, Inc. Cemsidomide IKZF1/3 2Q 2025: Completed Phase 1 dose escalation in MM September 2025: Present data from full Phase 1 dose escalation in MM at IMS Annual Meeting 4Q 2025: Present data from Phase 1 dose escalation data in